District Of Columbia is currently home to 851 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Washington, Washington, D.C., Washington DC and Washington, Dc. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Prospective Observational Study of the ICD in Sudden Cardiac Death Prevention
NCT00733590
Recruiting
The overall hypothesis of this study is that subtle interactions between structural (substrate) and functional (trigger) abnormalities of the heart, some of which are genetically-determined, can be used to identify patients at high risk of sudden cardiac death (SCD). Such information may be used to better define patients most likely to benefit from replacement of an internal defibrillator (ICD). The prospective, observational study to enroll, categorize and follow patients who receive an ICD pul... Read More
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
01/10/2025
Locations: Washington Hospital Center, Washington, District of Columbia
Conditions: Heart Failure, Congestive, Death, Sudden, Cardiac, Arrhythmia, Cardiomyopathies
Register for Updates
Outcomes of High-risk Non-muscle Invasive Bladder Cancer Treated With Blue Light Resection
NCT06525571
Recruiting
Comparing white-light cystoscopy (WLC) and blue-light cystoscopy (BLC) in TURBT for high risk (HR) non-muscle invasive bladder cancer (NMIBC) patients is crucial to determine the most effective method for reducing residual disease burden and improving recurrence-free survival. Enhanced visualization with BLC may lead to more accurate resections, potentially decreasing recurrence rates and improving long-term outcomes for bladder cancer patients. Patients will be randomized to either WLC TURBT or... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/09/2025
Locations: Sibley Memorial Hospital, Washington, District of Columbia
Conditions: Bladder Cancer
Register for Updates
Hospital to Home Study: Trial to Optimize Transitions and Address Disparities in Asthma Care
NCT05991115
Recruiting
Caregiver-child dyads will be recruited during child's hospital admission for asthma exacerbation. Recruitment sites will be mainly Children's National Hospital Sheikh Zayed campus, as well as regional partners: Holy Cross Hospital, and Mary Washington Hospital. After enrollment, baseline data will be collected from caregiver. Caregiver-child dyads will be randomized (1:1 ratio) into the control arm or intervention arm. Control arm will receive the standard of care after hospital discharge. Inte... Read More
Gender:
ALL
Ages:
Between 4 years and 12 years
Trial Updated:
01/09/2025
Locations: Children's National Hospital, Washington DC, District of Columbia
Conditions: Asthma, Asthma in Children
Register for Updates
Gender Related Coping and Survivorship for Genitourinary Cancers
NCT05649306
Recruiting
This research is being done to learn more about coping and survivorship of women with bladder cancer, specifically regarding psychosocial distress and sexual dysfunction. This study is a non-therapeutic study and will randomize participants to a standard of care group and education group. Patients in both groups will be asked to complete surveys regarding their mood and sexual function. Patients in the intervention group will be asked to complete attendance diaries regarding educational and supp... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
01/09/2025
Locations: Sibley Memorial Hospital, Washington, District of Columbia
Conditions: Bladder Cancer
Register for Updates
T-DM1 and Tucatinib Compared with T-DM1 Alone in Preventing Relapses in People with High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial
NCT04457596
Recruiting
This phase III trial studies how well trastuzumab emtansine (T-DM1) and tucatinib work in preventing breast cancer from coming back (relapsing) in patients with high risk, HER2 positive breast cancer. T-DM1 is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug, called DM1. Trastuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors, and delivers DM1 to kill them. Tucatinib may stop t... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/09/2025
Locations: Kaiser Permanente-Capitol Hill Medical Center, Washington, District of Columbia
Conditions: Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, HER2 Positive Breast Carcinoma, Invasive Breast Carcinoma, Multifocal Breast Carcinoma, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Synchronous Bilateral Breast Carcinoma
Register for Updates
EMAGINE 2.0 - Electromagnetic Field Ischemic Stroke - Novel Subacute Treatment
NCT06386874
Recruiting
This is a multicenter study that will be conducted at approximately 20 centers and up to 30 centers, if the sample size will be increased following interim assessment. The Q Therapeutic System (BQ 3.0) is a wearable medical device that produces and delivers non-invasive, extremely-low-intensity and low-frequency, frequency-tuned electromagnetic fields in order to stimulate neuronal networks with the aim of reducing disability and promoting neurorecovery. The Q Therapeutic System (BQ 3.0) is in... Read More
Gender:
ALL
Ages:
Between 22 years and 80 years
Trial Updated:
01/08/2025
Locations: MedStar National Rehabililtaion Hospital,, Washington, District of Columbia
Conditions: Ischemic Stroke
Register for Updates
Feasibility/Acceptability of Attentional-Control Training in Survivors
NCT05528939
Recruiting
This is a multicenter pilot randomized controlled trial, with an active control condition, of the feasibility, acceptability, and preliminary efficacy of EndeavorRx in a cohort of survivors of acute lymphoblastic leukemia or brain tumor ages 8-16 who are \> 1 year from the end of therapy.
Gender:
ALL
Ages:
Between 8 years and 16 years
Trial Updated:
01/08/2025
Locations: Children's National Hospital, Washington, District of Columbia
Conditions: Pediatric Cancer, Pediatric ALL, Pediatric Brain Tumor, Attention Difficulties, Cognitive Deficit in Attention
Register for Updates
Feasibility and Efficacy of Attentional-Control Training in Sickle Cell Disease
NCT05099874
Recruiting
Children with sickle cell disease (SCD) exhibit significantly reduced cognitive functioning (often difficulties with attention) compared to peers and siblings without SCD. EndeavorRx (Akili Interactive Labs: Boston, MA) is an FDA-approved home-based, electronic attentional-control training program designed to treat attention problems in youth. Users access EndeavorRx on a tablet device for 25-30 minutes each day, 5 days per week, for 4 weeks. The program involves training in a game-like environm... Read More
Gender:
ALL
Ages:
Between 8 years and 16 years
Trial Updated:
01/08/2025
Locations: Children's National Hospital, Washington, District of Columbia
Conditions: Sickle Cell Disease, Attention Deficit, Cognitive Deficit in Attention
Register for Updates
Pregnancy and Early Neurodevelopmental Outcomes Following In Utero Lyme Disease Exposure
NCT06026969
Recruiting
The purpose of this pilot study is to assess the feasibility of longitudinal neurodevelopmental evaluation of fetuses and infants exposed to Lyme disease in utero. Participants with Lyme disease or Post-Treatment Lyme Disease Syndrome (PTLDS) will be recruited during pregnancy. Pregnancies will be monitored and infant development will be assessed from birth until age 18 months.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/06/2025
Locations: Children's National Hospital, Washington, District of Columbia
Conditions: Lyme Disease, Post-Treatment Lyme Disease, Chronic Lyme Disease, Tick-Borne Infections, Pregnancy Complications, Child Development
Register for Updates
Multi-Center Molecular Diagnosis and Host Response of Respiratory Viral Infections in Pediatric Transplant Recipients
NCT05550298
Recruiting
The participants are being asked to take part in this clinical trial, a type of research study, because the participants are scheduled to receive or have recently received a hematopoietic cell transplant (HCT) or a solid organ transplant (SOT). Primary Objective To determine if pre-transplant screening for respiratory viral load predicts RVI within 1- year post-transplant among survivors. Secondary Objectives: * To develop and validate a classifier based on pre-transplant immunological profi... Read More
Gender:
ALL
Ages:
18 years and below
Trial Updated:
01/06/2025
Locations: Children's National Medical, Washington, District of Columbia
Conditions: Hematopoietic Cell Transplant, Solid Organ Transplant, Respiratory Viral Infection
Register for Updates
A Study of NST-6179 in Subjects With Intestinal Failure-Associated Liver Disease (IFALD).
NCT05919680
Recruiting
This is a phase 2a, multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of NST-6179 in subjects with intestinal failure-associated liver disease (IFALD) receiving parenteral nutrition (PN). The study will be conducted in 2 sequential parts. Up to 36 subjects diagnosed with IFALD will be enrolled in the study, of which up to 18 subjects will be enrolled in each of the 2 parts and randomized (2:1) t... Read More
Gender:
ALL
Ages:
16 years and above
Trial Updated:
01/05/2025
Locations: MedStar Georgetown University Hospital, Washington, District of Columbia
Conditions: Intestinal Failure Associated Liver Disease
Register for Updates
NPWT Reduction Mammaplasty
NCT06725459
Recruiting
In this prospective, randomized, split-body control trial, we aim to compare complications, patient-reported outcomes, and cost differentials following reduction mammaplasty with prophylactic closed incision negative pressure wound therapy versus standard adhesive dressing.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
01/03/2025
Locations: Medstar Georgetown University Hospital, Washington, District of Columbia
Conditions: Healthy, Macromastia, Negative Pressure Therapy, Mammaplasty, Wound Healing
Register for Updates